Researchers at the University of Alabama at Birmingham, and Southern Research, identified a drug candidate that they claim could potentially treat both 1 and type 2 diabetes. The small molecule drug, designated SRI-37330, inhibits the expression of a protein known as TXNIP—which the team had previously identified as a top glucose-induced gene—in both mouse and human islets. Results from preclinical studies suggested that SRI-37330 acts on pancreatic islet cells that produce glucagon and insulin, and reduced excess glucose production by the liver.
The companies said preliminary Phase I/II data from nearly 120 patients showed a more favorable overall tolerability profile than BNT162b1, with no serious adverse events and generally mild to moderate and transient systemic events such as fever, fatigue, and chills.
Novel technology could revolutionize production if biopharma industry can improve the quality of its manufacturing.
Gene therapy developers are advised to take a cue from how drugs were made not so long ago.
The Phase III COVE trial (NCT04470427) is designed to evaluate the safety of mRNA-1273 in 30,000 adult volunteers who do not have COVID-19. The primary endpoint will be the prevention of symptomatic COVID-19 disease. Key secondary endpoints include prevention of severe COVID-19 disease, as defined by the need for hospitalization), and prevention of infection by SARS-CoV-2.
DS-1062 is a trophoblast cell-surface antigen 2 (TROP2)-directed ADC that is now in Phase I clinical development for non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC).
A simple, rapid, and robust new COVID-19 test detects neutralizing antibodies to SARS-CoV-2 with high specificity and sensitivity and differentiates antibody responses to several human coronaviruses. The test does not require biosafety level 3 containment, making it broadly accessible to the wider community for both research and clinical applications.
Biomedical engineers at Tufts University School of Engineering have developed neurotransmitter-derived lipidoids that can help lipid nanoparticles to ferry therapeutic drugs and gene editing proteins across the blood-brain barrier in mice. The researchers believe the new technology could overcome many of the current limitations associated with delivering intravenously administered therapeutics into the central nervous system (CNS), and allow the use of a range of therapeutics that would otherwise not have access to the brain.
A high-resolution structure has been obtained for a ternary complex composed of two SARS-CoV-2 proteins, namely, the nonstructural proteins nsp16 and nsp10, and their viral mRNA substrate. During substrate binding, conformation changes consisted with the induced-fit enzyme model lead to methylation of the viral mRNA, which helps the viral mRNA evade the innate immune system. The structure also suggests the complex may be vulnerable to rationally designed antiviral drugs.
The U.S. Patent Trial and Appeal Board (PTAB) turns back Moderna’s argument that U.S. Patent No. 8,058,069 (‘069) should be overturned because the 22 claims covered by the patent could have been anticipated, and would have been obvious to a person having ordinary skill in the art to which the subject matter pertains.
Please wait while you are redirected to the right page...